Hansa Biopharma AB Stock price

Equities

HNSA

SE0002148817

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 07:59:48 2024-03-28 am EDT 5-day change 1st Jan Change
29.1 SEK -0.89% Intraday chart for Hansa Biopharma AB +0.34% +11.07%
Sales 2024 * 265M 24.73M Sales 2025 * 402M 37.57M Capitalization 1.55B 144M
Net income 2024 * -627M -58.53M Net income 2025 * -576M -53.77M EV / Sales 2024 * 8.68 x
Net Debt 2024 * 753M 70.27M Net Debt 2025 * 956M 89.25M EV / Sales 2025 * 6.22 x
P/E ratio 2024 *
-2.84 x
P/E ratio 2025 *
-3.46 x
Employees 168
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.60%
1 week+0.55%
Current month-7.84%
1 month-6.30%
3 months+3.40%
6 months-13.16%
Current year+11.30%
More quotes
1 week
28.10
Extreme 28.1
29.66
1 month
27.94
Extreme 27.94
32.62
Current year
25.00
Extreme 25
40.50
1 year
20.14
Extreme 20.14
58.10
3 years
20.14
Extreme 20.14
180.90
5 years
20.14
Extreme 20.14
288.60
10 years
11.80
Extreme 11.8
349.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 18-03-19
Chief Tech/Sci/R&D Officer 53 Nov. 30
Chief Tech/Sci/R&D Officer 66 20-05-28
Members of the board TitleAgeSince
Director/Board Member 73 18-05-28
Chairman 61 22-06-29
Director/Board Member 59 19-05-21
More insiders
Date Price Change Volume
24-03-28 29.1 -0.89% 46 968
24-03-27 29.36 +1.24% 41,619
24-03-26 29 0.00% 45,304
24-03-25 29 0.00% 73,120
24-03-22 29 0.00% 85,134

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 06:57 am EDT

More quotes
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company's operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS's goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company's patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
29.36 SEK
Average target price
112.5 SEK
Spread / Average Target
+283.17%
Consensus
  1. Stock
  2. Equities
  3. Stock Hansa Biopharma AB - Nasdaq Stockholm